Cenderitide structure
|
Common Name | Cenderitide | ||
---|---|---|---|---|
CAS Number | 507289-11-4 | Molecular Weight | 3745.27 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C158H263N49O50S3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of CenderitideCenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research[1][2][3]. |
Name | Cenderitide |
---|
Description | Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Cenderitide has antiproliferative, anti-fibrotic, and anti-hypertrophic properties[1]. |
In Vivo | In vivo in normal canines, Cenderitide (10, 50, and 100 ng/kg) is a potent cGMP stimulator that has renal enhancing and cardiac unloading effects, with less reduction of blood pressure[1][4]. |
Molecular Formula | C158H263N49O50S3 |
---|---|
Molecular Weight | 3745.27 |